Patents Assigned to DIATOS
-
Publication number: 20120010124Abstract: The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.Type: ApplicationFiled: June 16, 2008Publication date: January 12, 2012Applicant: DiatosInventors: Bertrand Alluis, Jean-Sebastien Fruchart
-
Patent number: 7884070Abstract: A peptide including a first peptide sequence of formula KLAKLAK (SEQ ID NO:11)in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula ?xx? (SEQ ID NO:13)in which ? is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.Type: GrantFiled: January 7, 2005Date of Patent: February 8, 2011Assignee: Diatos S.A.Inventor: Valérie Arranz
-
Publication number: 20100221235Abstract: The invention relates to chimeric polypeptides comprising a lysosomal peptide fused or conjugated to at least one cell-penetrating peptide (CPP). Also provided by the invention are methods for treating a subject suffering from lysosomal storage disorders (LSD).Type: ApplicationFiled: February 8, 2007Publication date: September 2, 2010Applicant: DiatosInventor: Valérie Arranz
-
Publication number: 20100035799Abstract: The present invention relates to a method for the preparation of a compound of formula (I) or pharmaceutically acceptable salts thereof and intermediates thereof, comprising the steps of: a) halogenating a compound of formula (II), resulting in compound of formula (IIa), b) reacting a compound of formula (IIa) at its 14 position with the thiol moiety of a peptide of formula (III), optionally in the presence of a suitable linker, to obtain said compound of formula (I), wherein R1 represents OH, NH2 or NH-peptide; R2 represents H or —CO-peptide; R3 represents OCH3, OH or H; R4 represents H, or COCF3; R5 represents OH, O-tetrahydropyranyl or H; R6 represents OH or H; R7 represents H, OH, OCO(CH2)3CH3 or OCOCH(OC2H5)2; R8 represents OH or H; R9 represents OH or H; R10 represents a halogen and L is an optional suitable linker arm.Type: ApplicationFiled: September 30, 2009Publication date: February 11, 2010Applicants: Universite Catholique de Louvain, Diatos S. A.Inventors: Anne-Marie Fernandez, Vincent Dubois
-
Publication number: 20100015136Abstract: The present invention relates to a novel compound of use in the improved delivery of therapeutic drug agents into target cells or tissues, composition comprising the same and uses thereof. The compound is more specifically a conjugate of a peptide moiety and a camptothecin, a derivative or analog thereof which provides numerous benefits, including enhancement in terms of aqueous solubility, pharmacokinetics and tissue distribution, enlargement of the therapeutic index, and limitation of the inter-patient metabolic variability, as well as improvement of delivery of the biologically active ingredient to the target cells or tissues.Type: ApplicationFiled: March 30, 2007Publication date: January 21, 2010Applicant: DIATOS, S.A.Inventors: Matthieu Michel, Denis Ravel, Fabien Ribes, Isabelle Tranchant
-
Publication number: 20090220529Abstract: This invention relates to the field of antibody-drug conjugates, and more particularly antibody-drug conjugates that are intended for the treatment and/or diagnosis of diseases such as tumors and/or inflammatory reactions.Type: ApplicationFiled: March 10, 2006Publication date: September 3, 2009Applicant: Diatos, S.A.Inventors: Andre Trouet, Vincent Dubois
-
Publication number: 20090186802Abstract: The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.Type: ApplicationFiled: June 16, 2008Publication date: July 23, 2009Applicant: DiatosInventors: Bertrand Alluis, Jean-Sebastien Fruchart
-
Patent number: 7544664Abstract: The present invention relates to an amino acid sequence being able to facilitate penetration of a substance of interest inside cells and/or cell nuclei and having the following formula (I) [(X1)p [(X)o (B)nX B X X B]m (X2)q wherein X1 and X2 are amino acid sequences of 1 to 20 amino acids; p and q are whole numbers between 0 and 5; B is a basic amino acid; X is a non-basic, preferably hydrophobic amino acid, such as alanine, isoleucine, leucine, methionine, phenylalanine, tryptophan, valine or tyrosine; n is 2 or 3; m is 1 to 4; o is 0 or 1, between 0 and 5; B is a basic amino acid; X is a non-basic, preferably hydrophobic amino acid, such as alanine, isoleucine, leucine, methionine phenylalanine, tryptophan, valine or tyrosine; n is 2 or 3; m is 1 to 4; o is 0 or 1.Type: GrantFiled: August 13, 2004Date of Patent: June 9, 2009Assignee: Diatos, S.A.Inventor: Alexandre Avrameas
-
Publication number: 20070259813Abstract: The invention relates to an anti-bacterial composition, especially for controlling gram-negative bacteria, containing a combination of: a) at least one peptide of between 10 and 25 amino acid residues comprising: i) two positively charged domains with a neutral pH consisting of between 3 and 9 amino acid residues, at least two thirds thereof being cationic amino acids, ii) a group of two to three non-cationic amino acid residues located between said positively charged domains, iii) a group of between 0 and 10, preferably between 0 and 5, amino acid residues selected from the group comprising non-hydrophobic amino acids and positively charged amino acids, located at one of the terminal ends N or C of the peptide, a positively charged amino acid residue, however, not being directly adjacent to the positively charged domains; and b) at least one anti-bacterial compound.Type: ApplicationFiled: August 13, 2004Publication date: November 8, 2007Applicant: DIATOSInventor: Valerie Arranz
-
Patent number: 7112562Abstract: The invention relates generally to chimeric peptides and compositions that facilitate the transport of insulin across biological membranes, methods for preparing the chimeric peptides, and a method for treating a subject suffering from diabetes.Type: GrantFiled: January 9, 2006Date of Patent: September 26, 2006Assignee: Diatos, S.A.Inventor: Jean-Leon Tchelingerian
-
Patent number: 7049286Abstract: The invention relates generally to chimeric peptides and compositions that facilitate the transport of insulin across biological membranes, methods for preparing the chimeric peptides, and a method for treating a subject suffering from diabetes.Type: GrantFiled: August 29, 2002Date of Patent: May 23, 2006Assignee: Diatos, S.A.Inventor: Jean-Leon Tchelingerian
-
Publication number: 20050277589Abstract: A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula ?xx? in which ? is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.Type: ApplicationFiled: January 7, 2005Publication date: December 15, 2005Applicant: Diatos S.A., a corporation of FranceInventor: Valerie Arranz